These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17160925)

  • 21. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R; Olea T
    Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fabry disease in children: agalsidase-beta enzyme replacement therapy.
    Borgwardt L; Feldt-Rasmussen U; Rasmussen AK; Ballegaard M; Meldgaard Lund A
    Clin Genet; 2013 May; 83(5):432-8. PubMed ID: 22880956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
    Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
    Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fabry disease.
    Germain DP
    Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
    Demontis R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The heart in Anderson Fabry disease.
    Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
    Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current management of Fabry disease].
    Cochat P; Liutkus A; Dubourg L; Levade T
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
    Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
    Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel α-Galactosidase A Mutation (K391E) in a Young Woman With Severe Cardiac and Renal Manifestations of Fabry Disease.
    Wakakuri H; Nakamura S; Utsumi K; Shimizu W; Yasutake M
    Int Heart J; 2016 Sep; 57(5):637-9. PubMed ID: 27593536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Results of enzyme replacement therapy in Fabry disease nephropathy].
    Dussol B
    Presse Med; 2007 Mar; 36 Spec No 1():1S43-7. PubMed ID: 17546767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Fabry disease : diagnosis and treatment].
    Üçeyler N; Sommer C
    Schmerz; 2012 Sep; 26(5):609-19. PubMed ID: 23052995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fabry disease in light of recent review].
    Uyama E
    Brain Nerve; 2008 Nov; 60(11):1235-44. PubMed ID: 19069157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous complications of Anderson-Fabry disease.
    Giuseppe P; Daniele R; Rita BM
    Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.